Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Using ctDNA to predict recurrence and response in colorectal cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.07.19
Views: 341

Dr Aparna Parikh - Massachusetts General Hospital Cancer Center, Boston, USA

Dr Aparna Parikh speaks to ecancer at ESMO 21st World Congress on Gastrointestinal Cancer about using cell-free circulating tumour DNA (ctDNA) to predict recurrence and response in colorectal cancer patients during adjuvant and neoadjuvant therapy.

She explains the method of genomic profiling they used to detect ctDNA after definitive therapy.

Dr Parikh concludes that not only can ctDNA be a marker of response to therapy, but that the kinetics of clearance can be indicative of time to recurrence.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation